EPITAC Trademark

Trademark Overview


On Tuesday, February 27, 2024, a trademark application was filed for EPITAC with the United States Patent and Trademark Office. The USPTO has given the EPITAC trademark a serial number of 98424138. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, January 7, 2025. This trademark is owned by EpiBiologics, Inc.. The EPITAC trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for the treatment and prevention of oncogenic and autoimmune diseases signals using protein degradation in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, pulmonology, pneumology, oncology, metabolism, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation using protein degradation for use in treating oncology indications, namely, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastrointestinal stromal tumor (GIST), Gastric, Muscle invasive bladder cancer (MIBC), Colorectal Carcinoma (CRC), and autoimmune disease, namely, Pemphigus Vulgaris, Myasthenia Gravis, Rheumatoid arthritis, and Lupus; pharmaceutical preparations for the treatment of infectious diseases, immunodeficiency diseases, metabolic disease, Urticaria, Masto...

Medical and pharmaceutical research services in relation to protein degradation; pharmaceutical research and development in relation to protein degradation; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services i...
epitac

General Information


Serial Number98424138
Word MarkEPITAC
Filing DateTuesday, February 27, 2024
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, January 7, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 7, 2025

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment and prevention of oncogenic and autoimmune diseases signals using protein degradation in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, pulmonology, pneumology, oncology, metabolism, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation using protein degradation for use in treating oncology indications, namely, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastrointestinal stromal tumor (GIST), Gastric, Muscle invasive bladder cancer (MIBC), Colorectal Carcinoma (CRC), and autoimmune disease, namely, Pemphigus Vulgaris, Myasthenia Gravis, Rheumatoid arthritis, and Lupus; pharmaceutical preparations for the treatment of infectious diseases, immunodeficiency diseases, metabolic disease, Urticaria, Mastocytosis, Asthma, Alzheimer’s disease, Parkinson’s Disease, Multiple sclerosis, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastrointestinal stromal tumor (GIST), Gastric, Muscle invasive bladder cancer (MIBC), Colorectal Carcinoma (CRC), and autoimmune disease, namely, Pemphigus Vulgaris, Myasthenia Gravis, Rheumatoid arthritis, and Lupus; pharmaceutical preparations, namely, targeted therapies that degrade disease driving membrane and extracellular proteins to treat oncology and autoimmune disease, namely, metabolic disease, Urticaria, Mastocytosis, Asthma, Alzheimer’s disease, Parkinson’s Disease, Multiple sclerosis, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastrointestinal stromal tumor (GIST), Gastric, Muscle invasive bladder cancer (MIBC), Colorectal Carcinoma (CRC), and autoimmune disease, namely, Pemphigus Vulgaris, Myasthenia Gravis, Rheumatoid arthritis, and Lupus
Goods and ServicesMedical and pharmaceutical research services in relation to protein degradation; pharmaceutical research and development in relation to protein degradation; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical and biopharmaceutical products; providing evaluation testing for pharmaceutical and biopharmaceutical products featuring protein degradation; pre-clinical and non-clinical evaluation testing of pharmaceutical and biopharmaceutical products; pharmaceutical and biopharmaceutical research and development featuring protein degradation for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, metabolism, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases; medical and pharmaceutical research in relation to targeted therapies that degrade disease driving membrane and extracellular proteins

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 27, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, February 27, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEpiBiologics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Mateo, CA 94403

Party NameEpiBiologics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Mateo, CA 94403

Trademark Events


Event DateEvent Description
Tuesday, February 27, 2024NEW APPLICATION ENTERED
Monday, July 8, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, September 16, 2024ASSIGNED TO EXAMINER
Tuesday, September 17, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 17, 2024NON-FINAL ACTION E-MAILED
Tuesday, September 17, 2024NON-FINAL ACTION WRITTEN
Tuesday, December 10, 2024EXAMINERS AMENDMENT -WRITTEN
Tuesday, December 10, 2024EXAMINERS AMENDMENT E-MAILED
Tuesday, December 10, 2024EXAMINER'S AMENDMENT ENTERED
Tuesday, December 10, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, December 10, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 1, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 7, 2025PUBLISHED FOR OPPOSITION
Tuesday, January 7, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED